Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer

Polish Journal of Pathology

Volumn 58, Issue 4, 2007, Pages 235-243

  Musiał, Jacek ^a   Sporny, Stanisław ^a   Nowicki, Andrzej ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Regional Specialistic Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EZRIN; UVOMORULIN;

ARTICLE; BIOPSY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STAINING; TUMOR DIFFERENTIATION;

CADHERINS; CYTOSKELETAL PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 41149126767     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Akisawa N: High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 1999, 258(2), 395-400.
2. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ: Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 2004, 10(20), 6770-6778.
3. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hoefler H: E-Cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Research 1994, 54, 3845-3852.
4. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Marcel MM, Birchmeier W: Loss of epitheial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/α-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol, 120, 757-766, 1993.
5. Berx G, Becker KF, Hofler H, van Roy F: Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998, 12, 226-237.
6. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers M, van Bokhoven A, van Roy F: Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 1995, 26, 281-289.
7. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996, 148, 1375-1380.
8. Christofori G: The role of the cell-cell adhesion molecule E-cadherin as a tumour supressor gene. Trends Biochem Sci 1999, 24, 73-76.
9. Davies G, Jiang W, Mason M: Cell-cell adhesion and signalling intermediates in human prostate cancer. J Urol 2000; 163, 985-992.
10. De Marzo A, Knudsen B, Chan-Tack K, Epstein J: E-cadherin expression as a marker of tumour aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53, 707-713.
11. Efstathiou J, Liu D, Wheeler J, Kim H, Beck N, Ilyas M, Karayiannakis A, Mortensen N, Kmiot W, Playford R, Pignatelli M, Bodmer WF: Mutated epithelial cadherin is associated with increased tumorigenicity and los of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. PNASOnline 1999, 96, 2316-2321.
12. Fais S: A role for ezrin in a neglected metastatic tumor function. Trends Mol Med 2004, 10(6), 249-250.
13. Fiévet B, Louvard D, Arpin M: ERM proteins in epithelial cell organization and functions. Biochimica et Biophysica Acta 2007, 1773, 653-660.
14. Geiger K, Stoldt P, Schlote W, Derouiche A: Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 2000, 157, 1785-1793.
15. Harrison GM, Davies G, Martin TA et al: Distribution and expression of CD44 isoforms and ezrin during prostate cancer-endothelium interaction. Int J Oncol 21: 935-940, 2002.
16. Hiscox S, Wen G: Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/b-catenin. J Cell Sci 1999, 112, 3081-3090.
17. Hunter K: Ezrin, a key component in tumor metastasis. Trends Mol Med 2004, 10(5), 201-204.
18. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001, 61, 3750-3759.
19. Makitie T: Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest. Ophthalmol Vis Sci 2001, 42, 2442-2449.
20. Mason M, Gaynor D, Wen G: Cell adhesion molecules and adhesion abnormalities in prostate cancer. Critical Reviews in Oncology/Hematology 2002, 41, 11-28.
21. Moilanen J et al: Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003; 90(2): 273-81.
22. Morton R, Ewing C, Nagafuchi A, Tsukita S, Isaacs W: Reduction of E-cadherin levels and deletion of the a-catenin gene in human prostate cancer cells. Cancer Res 1993, 53, 3585-3590.
23. Ohtani K, Sakamoto H, Rutherford T: Ezrin, a membrane/cytoskeletal linking protein is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Letter 2002, 179, 79-86.
24. Pećina-Šlaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003, 3, 17.
25. Rhodes D, Sanda M, Otte A, Chinnaiyan A, Rubin M: Multiplex biomarker approach for determining risk of prostatespecific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003, 9, 661-668.
26. Richmond P, Karayiannakis A, Nagafuchi A, Kaisary A, Pignatelli M: Aberrant E-cadherin and alpha-catenin expression in prostate cancer. Correlation with patient survival. Cancer Res 1997, 57, 3189-3193.
27. Ryan C, Small E: Advances in prostate cancer. Curr Opin Oncol 2004, 16(3), 242-246.
28. Sarrió D, Rodríguez-Pinilla S, Dotor A, Calero F, Hardisson D, Palacios J: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006, 98(1), 71-79.
29. See-Tong Pang, Xioalei F, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P: Expression of ezrin in prostatic intraepithelial neoplasia. Urology 2004, 63, 609-612.
30. Shapiro L, Fannon A, Kwong P, Thompson A, Lehmann M, Grubel G, Legrand J, Alsnielsen J, Coleman D, Hendrickson W: Structural basis of cell-cell adhesion by cadherins. Nature 1995, 374, 327-337.
31. Tsukita S, Yonemura S: ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997, 9, 70-75.
32. Umbas R, Schalken J, Aalders T, Carter B, Karthaus H, Schaafsma H, Debruyne F, Isaacs W: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52, 5104-5109.
33. Umbas R: Decreased E-Cadherin Expression Is Associated with Poor Prognosis in Patients with Prostate Cancer. Cancer Res 1994, 54, 3929-3933.
34. Umbas R, Schalken IA, Aalders T, Carter B, Karthaus H, Schaafsma H, Debruyne F Isaacs B: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52, 5104-5109.
35. Valdman A, Xiaolei F, See-Tong P, Nilsson B, Ekman P, Egevad L: Ezrin Expressionin Prostate Cancer and Benign Prostatic Tissue European. Urology 2005, 48, 852-857.
36. Vera L: Focus on Molecules: Ezrin. Experimental Eye Research 2007, 84, 613-614.
37. Vleminckx K, Vakaet L, Mareel M, Fiers W, Van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66, 107-119.